Fig. 1: xCT is highly expressed in patients with primary CRC and predicts a poor prognosis. | Cell Death & Disease

Fig. 1: xCT is highly expressed in patients with primary CRC and predicts a poor prognosis.

From: xCT contributes to colorectal cancer tumorigenesis through upregulation of the MELK oncogene and activation of the AKT/mTOR cascade

Fig. 1

A Differences in the expression of xCT between tumors and normal tissues of various organs were observed in the TCGA database. B An overall exploration of the expression characteristics of xCT in the TCGA pancancer dataset. C, D Difference in the expression of xCT between patients with COAD or READ and matched normal samples in the TCGA database. E Difference in the expression of xCT between 203 CRC samples and 160 mucosa control samples in the GSE87211 dataset. F Difference in the expression of xCT between CRC samples and matched normal samples from our collected 49 CRC subjects was assessed using IHC staining. G IHC staining showed that xCT was more positively expressed in CRC tissues than in normal tissues from our collected CRC samples. H Western blot analysis showed that the expression of xCT was higher in CRC tissues than in normal tissues. I Relationship between xCT expression and clinicopathological characteristics in CRC patients from our collected CRC samples. J The prognosis of CRC patients with high expression of xCT was worse than that of CRC patients with low expression of xCT in GSE87211. K The ROC curve shows that xCT levels could predict the prognosis of CRC patients with great accuracy. L CRC patients with high expression of xCT had a poorer prognosis than those with low expression of xCT in our validation cohort. M The ROC curve confirmed the prognostic predictive accuracy in our validation cohort. **P < 0.01, ****P < 0.0001.

Back to article page